Induction of a potent neutralizing antibody response capable of recognizing highly diverse isolates of HIV-1 is one of the most important goals of HIV vaccine research. This represents a considerable ...
Therefore, we administered a third 30-μg BNT162b2 dose 7.9 to 8.8 months after dose 2 to 11 participants 18 to 55 years of age and to 12 participants 65 to 85 years of age from U.S. sites in the phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback